Implementation of PROs in daily oncology care before and during the SARS-CoV-2 pandemic : real world experience

Source
Antwerpen, Universiteit Antwerpen, Faculteit Geneeskunde en Gezondheidswetenschappen, 2023,120 p.
Author(s)

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer

Source
Clinical cancer research - ISSN 1078-0432-29:3 (2023) p. 635-646

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Source
Cancer immunology and immunotherapy - ISSN 0340-7004-72:2 (2023) p. 475-491
Author(s)
    Emiel A. De Jaeghere, Sandra Tuyaerts, An M.T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter André Van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore G. Denys

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors

Source
Frontiers in immunology - ISSN 1664-3224-13 (2022) p. 1-10
Author(s)